Michael Carleton Email and Phone Number
Michael Carleton work email
- Valid
- Valid
- Valid
- Valid
Michael Carleton personal email
Michael Carleton phone numbers
Accomplished and highly motivated scientific research and development leader with expertise in cell/molecular biology and translational science spanning 20+ years. Demonstrated expertise in preclinical biomarker identification and clinical translation of biomarkers, small molecule inhibitors and antibody therapeutics in oncology, immune oncology, and chronic liver disease. Facility with design and execution of MOA, DMPK, and PD directed studies in models of human cancer (human tumor xenografts and murine syngeneic tumors) and models of NAFLD/NASH/cholestasis. Experience managing IND-enabling studies for small molecule inhibitors. Strong communicator and team player with people and project management skills obtained and developed from a wide array of collaborations and leadership positions within academic, large pharma, and small biotech sectors. A record of execution across a diverse set of scientific disciplines including oncology, immunology, hepatology, genomics, virology, and bacteriology.
The Mark Foundation For Cancer Research
View- Website:
- themarkfoundation.org
- Employees:
- 15
-
Senior Scientific DirectorThe Mark Foundation For Cancer ResearchHoodsport, Wa, Us
-
ConsultantDeerfield Management Apr 2022 - Present -
Senior Scientific DirectorThe Mark Foundation For Cancer Research Feb 2020 - Present
-
Advisor Translational MedicineAprea Therapeutics Mar 2021 - PresentUnited StatesManaged IND-enabling studies and successful IND application to FDA for APR-1051 (WEE1 inhibitor) -
Vice President, Translational MedicineInipharm Aug 2019 - Mar 2023Managed pre-clinical studies in support of INI-822, Inipharm's HSD17B13 inhibitor clinical lead under development for fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).
-
Vice President, Translational MedicineMavupharma Apr 2019 - Jul 2019Supported pre-clinical development of MAVU-104, a first-in-class, orally active, small molecule inhibitor of ENPP1, an enzyme involved in the regulation of the STING pathway. Inhibiting ENPP1 activity with MAVU-104 allows for highly controlled enhancement of STING signaling in tumors without the need for injections. Mavupharma and the ENPP1 program was purchased by Abbvie in 2019.
-
Director, Clinical MechanismsBristol Myers Squibb Apr 2018 - Apr 2019Princeton NjLed pre-clinical and clinical efforts across matrix team to define and confirm mechanism(s) of action for selected IO assets and combinations for:-Innate immune cell agonists-Monocyte and myeloid cell agonists/depletors-Tumor and immune cell metabolismProvided subject matter expertise for due diligence activities and external project reviewsDeveloped and managed external collaborations in support of IO portfolio -
Director, Translational ResearchBristol Myers Squibb Aug 2017 - Apr 2018Princeton NjLed efforts to integrate and analyze clinical datasets to facilitate: prospective patient segmentation into responder and non-responder populationsunderstanding(s) of IO mechanisms of resistance rational selection of IO therapeutic combinationsidentification of clinical correlates of response within the tumor microenvironmentProvided subject matter expertise for due diligence activities and external project reviewsManaged external collaborations in support of IO portfolio
-
Director, Oncology BiomarkersBristol Myers Squibb Nov 2015 - Jul 2017Princeton Nj-Directed IO biomarker strategy for Nivolumab in GBM Phase 2 and Phase 3 trials-Developed and translated IO biomarker plan for anti-CSF-1R Ph1a/b trial -Directed development of IO biomarker plan for anti-IL8 program-Worked within matrix environment to develop clinical strategy for anti-IL-8 and anti-CSF-1R-Worked within matrix environment to drive selection and clinical development of IO combinations-Managed external collaborations in support of IO portfolio-Provided subject matter expertise for due diligence activities and external project reviews
-
Senior DirectorPresage Biosciences, Inc. Jan 2013 - Oct 2015Seattle Wa-Directed pre-clinical indication finding studies for internal drug development programs. -Directed research program focused on applying Presage proprietary intra-tumoral injection technology for the purpose of detecting localized immune responses within relevant tumor models in response to local injection of anti-cancer immune-modulatory agents.-Managed Presage/Celgene collaboration focused on application of Presage proprietary intra-tumoral injection platforms to combination drug efficacy screens in selected DLBCL and solid tumor xenografts. -
Senior DirectorMatrix Genetics May 2012 - Jan 2013Seattle Wa-Led metabolic engineering efforts for enhanced production of lipid in cyanobacteria-Primary investigator for TGI as part of DOE funded National Alliance for Advanced Biofuels and Bio-products (NAABB) -
Senior Director Core TechnologiesTargeted Growth Aug 2010 - Apr 2012Seattle Wa-Primary investigator for TGI as part of DOE funded National Alliance for Advanced Biofuels and Bio-products (NAABB)-Led transcriptomics, metabolomics, next generation sequencing efforts in cyanobacteria -Led genetic screening and molecular tool development efforts in cyanobacteria -Established methods for wheat and corn genotyping -
Director Core TechnologiesTargeted Growth Sep 2008 - Sep 2010Seattle Wa-Directed efforts to establish and apply transcriptomics to metabolic engineering of cyanobacteria-Directed efforts to apply context-specific genetic screens to gene discovery/pathway annotation of cyanobacteria-Directed efforts to establish GC and HPLC methods for metabolite analysis in cyanobacteria-Directed efforts to establish flow cytometry and microscopy methods for lipid body characterization and bacterial enumeration-Directed efforts to identify and validate cyanobacteria promoter elements for use in transgene expression studies
-
Research FellowRosetta Inpharmatics Feb 2006 - Sep 2008Seattle Wa-Led efforts to translate/apply pharmacodynamic and response biomarkers to four phase I oncology clinical programs-Led efforts to apply lentiviral shRNA expression to investigate BRCA1 pathway function and synthetic lethality of PARP inhibition.-Led HTS efforts to identify/characterize mircoRNAs that disrupt cell cycle progression in tumor cells-Led efforts to identify microRNAs that function in myoblast, osteoblast, and T cell differentiation -
Senior Research ScientistRosetta Inpharmatics Nov 2001 - Jan 2006Seattle Wa-Led efforts to clone novel sphingosine phosphohydrolase (SPP2) and characterize its role in modulating S1P signaling-Led efforts to characterize the function of mitotic kinesin KIF14-Led HTS efforts to generate stable TP53 shRNA expressing cell lines -Led efforts to validate and characterize TP53 context specific genes identified in genome-wide chemosensitization RNAi-based screens-Led efforts to develop cell-based assays for screening small molecule ubiquitin ligase inhibitors in collaboration with Rigel Phamaceuticals-Collaborated on efforts to develop/optimize genome scale HTS methods for full genome siRNA screens as part of oncology target ID/validation efforts
-
Arthritis InvestigatorFox Chase Cancer Center Jul 2001 - Oct 2001Philadelphia Pa-Identified and studied gene expression changes mediated by early growth response transcription factors and Notch during thymocyte development -
Postdoctoral FellowFox Chase Cancer Center Feb 1997 - Jun 2001Philadelphia PaAdvisor: David L. Wiest-Determined early growth response transcription factors are necessary for thymocyte progression through the beta-selection checkpoint-Established a cell culture-based system to study the role of pre-TCR signaling in thymocyte development
Michael Carleton Skills
Michael Carleton Education Details
-
Microbiology -
Microbiology
Frequently Asked Questions about Michael Carleton
What company does Michael Carleton work for?
Michael Carleton works for The Mark Foundation For Cancer Research
What is Michael Carleton's role at the current company?
Michael Carleton's current role is Senior Scientific Director.
What is Michael Carleton's email address?
Michael Carleton's email address is mc****@****arm.com
What is Michael Carleton's direct phone number?
Michael Carleton's direct phone number is (212) 546*****
What schools did Michael Carleton attend?
Michael Carleton attended The University Of Texas At Austin, The University Of Texas At Austin.
What skills is Michael Carleton known for?
Michael Carleton has skills like Biochemistry, Assay Development, Genetics, Cell, Flow Cytometry, Biotechnology, Protein Chemistry, Immunology, High Throughput Screening, Dna Sequencing, Biomarkers, Microscopy.
Who are Michael Carleton's colleagues?
Michael Carleton's colleagues are Anna Turetsky, Becky Bish, Janice Lin, Rebecca Liu, Ryan Schoenfeld.
Not the Michael Carleton you were looking for?
-
Michael Carleton
Canandaigua, Ny -
Michael Carleton
Bronx, Ny5hotmail.com, hotmail.com, arachnidsystems.com, hotmail.com, gmail.com4 +191466XXXXX
-
2hgbev.com, gmail.com1 1732742XXXX
-
2msu.edu, grahampackaging.com
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial